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A B S T R A C T
Background: The incidence rate of hip fractures seems to be declining in many western countries. However, due
to the ageing of the population, the number of fractures may still be on the rise. No papers so far have quantified
the future burden of hip fractures in terms of both health loss (as measured in disability adjusted life years DALY)
and costs. The purpose of this paper is to assess the future health and economic burden of hip fractures.
Methods: We collected population projections from Statistics Norway up until the year 2040. The medium
projection was used for the base case analysis. Fracture rates for 2008 were estimated based on information from
the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS) hip fracture database (NORHip), which includes
information about all hip fractures in Norway. Future fracture rate was assumed to decline by 0.7% per year in
the base case. We used the same assumptions as the global burden of disease project on years of remaining life
and disability weights. Cost of hip fracture was based on the published literature.
In sensitivity analyses, we assessed the impact of changing underlying assumptions on demographic change,
development in hip fracture rate, assumed life expectancy and choice of disability weights.
Results: Assuming a medium population growth and a continued decline in fracture rate, our estimates indicate
that health lost to hip fractures will approximately double, from 32,850 DALYs in 2020 to 60,555 in 2040. Over
the same period, costs are estimated to increase by 65%.
Sensitivity analyses indicate that estimates are highly sensitive to assumptions on both population growth,
fracture rate development, disability weights and assumed life expectancy.
Conclusion: The burden of hip fractures in terms of DALYs lost and cost incurred is likely to increase even if the
fracture rate continues to decline.
1. Introduction
Recent research indicates that the age specific incidence of hip
fractures may be declining in many Western countries [1,2] including
Norway [3,4]. However, given an ageing population, the absolute
number of hip fractures may still be on the rise [5]. Estimates indicate
that by 2050, 20% of the Norwegian population will be 70 years old or
older, compared to 12% today [6]. This population growth will greatly
increase the population at risk of hip fractures and potentially the
health and economic burden of hip fractures.
The burden of hip fractures is twofold, as fractures affect both the
health of individuals and societal cost. The health burden of hip frac-
tures manifests as both disability [7] and mortality [8]. One summary
measure of the health burden is the Disability Adjusted Life Year
(DALY), consisting of years of life with disability and years of life lost
due to premature mortality [9]. The DALY is the measure of health
burden used by the WHO in the Global Burden of Disease Project (GBD)
[10]. The cost of hip fractures results from the cost of acute care, but
also from rehabilitation efforts and changes in living arrangements
following functional decline.
To our knowledge, only two studies have attempted to estimate the
burden of hip fractures in terms of DALYs. One is a study from Iran
[11]; the other is a study pooling information from 14 European and US
cohort studies (CHANGES consortium) [12]. No published studies have
projected the future health burden in terms of DALYs.
A number of cost projections already exist for different countries
[13–21]. Early papers [20,21] tended to assume that age specific in-
cidence would continue to increase, whereas more recent work has
generally assumed a constant future rate of fractures [19]. Cost pro-
jections have largely neglected to account for the combined effect of
changes in fracture rates and population ageing. Accurate projections
not only depend on demographic changes, but also on assumptions
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about future fracture risk, thus new projections on future burden of hip
fractures are warranted [22].
On this background, the aim of the current paper is threefold: (1) to
estimate the current burden of hip fractures in Norway in terms of
DALYs and health care costs, (2) to project the future health and eco-
nomic burden, and (3) to assess the impact of the estimated projections
by changing underlying assumptions about population growth, changes
in incidence rates, choice of disability weights and assumed life ex-
pectancy.
This paper adds to the current literature by projecting both health
and cost consequences of hip fractures. We also quantify how sensitive
estimates of health burden of disease are to assumptions about life
expectancy and choice of disability weights.
2. Methods
Current burden was calculated by multiplying the number of frac-
tures by estimates of health care unit costs and current health burden in
DALYs. For future projections, the number of fractures in each year was
calculated by multiplying the number of eligible individuals in the
different population projections by the assumed future age and gender
specific fracture rates. Different scenarios based on different assump-
tions about input parameters supplement our best guess analysis.
2.1. Number of current hip fractures
Fracture rates for 2008 were estimated based on information from
the Norwegian Epidemiologic Osteoporosis Studies (NOREPOS) hip
fracture database (NORHip), which includes information about all hip
fractures in Norway [3,23]. The NORHip database was created using
information on hip fractures gathered from the patient administrative
system of all Norwegian hospitals treating hip fractures through a
procedure developed by the Norwegian Knowledge Centre for the
Health Services. In total 139,913 new hip fractures were identified from
1 January 1994 to 31 December 2008. Age and gender specific number
of fractures in 2008 were combined with population information from
Statistics Norway on population at risk, defined as the mid-year po-
pulation 50 years or older, in order to estimate incidence rates.
2.2. Health lost due to a hip fracture
We measured health lost due to hip fractures in Disability Adjusted
Life Years (DALYs). The DALY combines the effects of mortality and
disability following a fracture into one summary measure. The DALY
consists of two components, years of life lost (YLL) and years lived with
disability (YLD) [24].
= +DALY YLL YLD (1)
YLL was calculated using mortality rates from Statistics Norway,
adjusted to reflect the increased mortality following an incident hip
fracture using a hazard ratio of 2.0, based on an estimate from a
Norwegian study [25]. Since the applied hazard ratio of dying was
based on an analysis that adjusted for a number of covariates, we as-
sumed that the remaining effect was causally related to a hip fracture
and made no further adjustments. This post fracture mortality rate was
multiplied by expected length of remaining life as used in the GBD
project estimated by Coale and Guo [26]. We applied uniform age
weighting.
= ∗ ,YLL N L (2)
where N is number of deaths and L is life expectancy at age of death.
A discount rate of 3% was applied in order to make estimates
comparable to other studies [27].
In order to calculate YLD, we multiplied the age and gender specific
hip fracture rate by the expected duration of impairment and a dis-
ability weight.
= ∗ ∗   YLD Incidence duration of disease disability weight (3)
Because hip fractures have been found to have an effect on both
short and long-term quality of life, we estimated both a short and long-
term loss. Based on findings by Bertram and co-workers [7], we as-
sumed the duration of short-term disability to be six months. We ap-
plied disability weights of 0.228 for short-term disability and 0.057 for
long-term disability, taken from a European update of the Global
burden of Disease project by Haagsma and colleagues [28]. Because the
long-term disability weight could be viewed as too low given that many
patients suffer serious impairments [7,29], we assumed that this long-
term weight represents the average impairment among all patients and
not a weight to be assigned only to those with moderate or severe hip
sequela.
2.3. Cost of a hip fracture
The cost of a hip fracture depends on the patient care pathway.
Almost all patients sustaining a hip fracture will need surgery. Different
types of surgery are available depending on the nature of the fracture
(dislocated or un-dislocated fractures) and the surgeon's advice. Based
on information from the Norwegian hip fracture registry (https://www.
kvalitetsregistre.no/registers/nasjonalt-hoftebruddregister), we as-
sumed that 40% of the fractures would need prosthesis, while 60%
would rely on surgery using other, less expensive techniques, such as
parallel screws. Based on national tariffs, the cost of prosthesis is
€14,702, while cost of parallel screws is €8036, resulting in a weighted
average of €10,703.
For other costs related to hip fracture, we based our estimate on a
published randomized controlled trial of orthogeriatric care in Norway
[30]. One limitation with this study was that patients already residing
in a nursing home at the time of the fracture were excluded from the
trial. Patients living at home at the time of the fracture have been
shown to suffer the more expensive fractures [31,32], as the marginal
impact of a fracture on living conditions are less dramatic for patients
already residing in a nursing home. We assumed that patients residing
in nursing homes would only incur operation costs causally related to
the fracture event. Approximately 25% of all fractures occur among
long-term care patients [33]. To further adjust for the fact that some of
the costs in the year following the fracture event would have been in-
curred independent of the fracture [34], we used an adjustment factor
based on a Canadian study [35] that estimated that 70% of the costs are
causally related to the hip fracture.
2.4. Future number of hip fractures
Demographic projections were obtained from Statistics Norway for
the period 2014 to 2040. The medium projection alternative was used
in our base case analysis. For the fracture rate, we assumed a continued,
but somewhat reduced decline in fracture rate (half of the decline ob-
served in the period 1994 to 2008).
2.5. Sensitivity analyses
We explored the uncertainty in the number of future fractures
arising from choice of demographic projection and uncertainty in
fracture rate development. In addition, we changed the underlying as-
sumption in the DALY calculations with regard to number of expected
life years and disability weights, in order to assess the impact of the
estimated future health burden.
2.5.1. Demographic change and incidence rate of hip fractures
Statistics Norway has three main projections that are based on dif-
ferent assumptions about fertility, mortality and immigration. While
the medium projection was used in the base case, we explored the
impact of using the low and high population projections in sensitivity
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analysis.
For the incidence rate, we explored the impact of assuming a con-
stant future fracture rate. The assumption being that the fracture rate
had reached a minimum and would remain constant over time. Given
that the future rate development is uncertain, we also explored a sce-
nario assuming a continued decline in the fracture rate of the same
magnitude as that observed in the period 1999–2008, i.e. a decline of
1.4% per year [5].
Together with the base case, these changing assumptions constitute
five different scenarios for future number of fractures and, thus, alter-
native health loss and cost projections. The five scenarios are: [1]
medium population growth and a half decline in fracture rates (i.e.
0.7% per annum), [2] low population growth combined with continued
decline in fracture rates, [3] high population growth with constant
fracture rates, [4] medium population growth with constant fracture
rates and [5] medium population growth with continued decline in
fracture rates.
2.5.2. Disability weights and choice of life expectancy
The health burden of hip fractures as measured in DALYs is natu-
rally sensitive to choice of disability weights. We explored this un-
certainty in a sensitivity analysis by replacing the GBD Haagsma
weights [28] with the weights proposed by the International Osteo-
porosis Foundation (IOF) [36]. The IOF weights are 0.468 for the first
year after fracture and 0.17 for subsequent years. We also applied
Norwegian estimates of remaining life-years produced by Statistics
Norway instead of the GBD estimates [26].
3. Results
3.1. Current health and economic burden of hip fractures
Current burden of hip fractures in terms of number of fractures,
deaths, years of life lost, years of life with disability, DALYs, costs of
surgery and total health and social care costs are displayed in Table 1.
Based on 9978 hip fractures, the current health burden in terms of
DALYs is 16,791 and 16,058 in women and men, respectively. In terms
of cost, hip fractures pose a burden on the health system of €107 million
for surgery, and of €348 million when the effect of rehabilitation and
changes in living situation are also included. In the current situation,
most of the health lost and costs incurred result from fractures in
women.
In terms of the different components of DALYs, we see that for men,
disability is the greatest contributor to the DALYs until they reach their
mid-60s, after which the mortality component is the main driver. For
women, the disability factor is the largest contributor until they reach
their 80s.
3.2. Future health and economic burden of hip fractures
Women lose more health to disability resulting from fractures than
men, while men lose more life years. In terms of health burden, women
currently lose more health to hip fractures than men, but this is ex-
pected to change around 2022, c.f. Fig. 1, left panel. Our estimates
indicate that in the period from 2020 to 2040 health lost to hip frac-
tures will approximately double, from approximately 32,850 DALYs in
2020 to approximately 60,555 in 2040. This is assuming the base case
projection with a medium population growth and a continued, but re-
duced, decline in fracture incidence.
Given the base case projection, costs are expected to increase by
65% by 2040 compared to the current situation. As with health loss, the
relative increase for men is expected to be much larger than for women
(100% vs 42% increase respectively, c.f. Fig. 1, right panel).
When we split the estimated health burden on different age groups,
we see that the increased health burden is clearly most pronounced in
the oldest age groups, i.e. age 80–84 years old (71% increase),
85–89 years old (109% increase) and 90–94 (121% increase), c.f. Fig. 2.
3.3. Sensitivity analyses
3.3.1. Assumptions about demographic changes and incidence rates of
fractures
The magnitude of the increase in the number of fractures is highly
dependent on the assumptions about both demographic and fracture
rate development. The increase in number of fractures varies from a
17% increase in the most conservative estimate (low population
growth, continued decline in fracture rate) to a 131% increase in a more
pessimistic scenario, assuming high population growth combined with
a constant future fracture rate.
In Fig. 3, we have calculated the health and economic burden of hip
Table 1
Current health and economic burden of hip fractures (2020).
Age group Individuals Fractures Deaths caused by hip fracture Remaining life years YLL⁎ YLD DALYs⁎ OP cost (€) Total cost (€)
Women
50–54 181,197 74 1 38 17 164 181 788,355 2,574,747
55–59 161,842 143 2 33 36 280 317 1,530,630 4,998,997
60–64 151,569 245 4 28 85 416 501 2,622,270 8,564,265
65–69 137,708 411 11 24 184 592 776 4,393,945 14,350,512
70–74 132,239 660 29 19 424 786 1210 7,060,708 23,060,090
75–79 93,388 996 61 15 749 954 1703 10,658,755 34,811,219
80–84 64,397 1198 159 12 1543 888 2431 12,826,257 41,890,223
85–89 43,473 1498 398 8 2895 828 3723 16,033,364 52,364,552
90–94 23,038 1197 1079 6 5472 478 5949 12,809,278 41,834,771
Sum women 988,851 6421 1744 11,405 5386 16,791 68,723,563 224,449,376
Men
50–54 194,505 97 2 38 47 216 263 1,037,084 3,387,089
55–59 171,061 121 4 33 91 237 327 1,291,779 4,218,917
60–64 154,838 162 12 28 227 276 503 1,738,789 5,678,840
65–69 136,591 274 25 24 432 396 828 2,935,251 9,586,454
70–74 126,709 471 62 19 915 561 1476 5,036,704 16,449,743
75–79 82,469 518 131 15 1613 496 2109 5,543,843 18,106,048
80–84 48,416 652 277 12 2696 483 3179 6,974,472 22,778,445
85–89 26,625 760 462 8 3358 420 3778 8,134,283 26,566,357
90–94 10,441 502 669 6 3394 200 3594 5,375,472 17,556,152
Sum men 951,655 3557 1646 12,774 3284 16,058 38,067,677 124,328,045
Total 1,940,506 9978 3390 24,179 8671 32,850 106,791,240 348,777,421
⁎ Discounted by 3%.
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fractures under different assumptions of population ageing and fracture
rate development. The total burden in terms of both health loss and
costs are likely to increase under all assumptions analyzed. The mag-
nitude of the burden varies from an estimated 44,500 DALYs and 18%
cost increase by 2040 in the “best case scenario” to 78,000 DALYs and
97% cost increase in the “worst case scenario”. Note that we have not
included a scenario with an increasing fracture rate, which would have
generated an even greater burden.
3.3.2. Choice of disability weights and life expectancy
If instead of the GBD disease weights, we use those proposed by the
IOF, the estimated health loss increases by approximately 50% (varies
somewhat between years). An additional effect of changing the disease
weights is that disability in women becomes the largest component of
the health loss until the year 2028, after which it is overtaken by life
loss in men, c.f. Fig. 4, top right panel. This is contrary to the findings
using the GBD disease weights, where years of life lost in men is the
largest contributor.
If we, instead of the GBD remaining life years, use Norwegian
gender specific estimates, the estimated total health lost to hip fractures
is 60% lower, from 83,126 DALYs to 34,367 DALYs in the year 2040.
Internal ranking of contributors to the DALYs are not affected by
changing life expectancy reference, but curves shift downwards.
4. Discussion
Our study adds to the existing body of literature by providing a
projection of both the health and economic burden of hip fractures,
while also accounting for recent fracture rate developments. It illus-
trates that the burden of hip fractures is likely to increase, even if the
incidence rates continue to decline. Health loss to hip fractures is likely
to double by 2040 and cost may exhibit a 65% increase.
We find that, currently, 32,850 DALYs are lost to hip fractures. The
GBD study [37,38] does not report on hip fractures as a separate injury
or disease, but estimates DALYs lost to fall injuries. To our knowledge,
included in fall injuries are all fractures, both low- and high-energy
fractures, as well as all fracture types. Compared to their estimates of
health loss to fall injuries, our estimate indicates a larger loss in lifetime
(24,179 vs. 8535) and a lesser loss in disability (8671 vs. 17,596). One
problem with this comparison is that fall injuries encompass several
types of injuries and a broader age range than our estimate.
Compared to the two published studies on fracture burden in terms
of DALYs, our calculations are based on an estimated 9978 fractures as
compared to 10,119 in Iran [11] and 7724 in a mixed European and US
cohort, CHANCES [12]. If we compare the findings based on no age
weighting, we find a burden of 32,850 DALYs as compared to 26,600 in
Iran and 11,145 in the mixed European and US cohort [12]. Contrary to
the overall findings based on the CHANCES cohort [12], we find that
mortality constitutes to be the largest contributor to health loss after











































Fig. 2. Future health loss (DALY) by age group.
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consortium was both the Norwegian Tromsø study and the Swedish
mammography cohort. Since life expectancy and rate of fractures vary
geographically [20], we also compared our results to these sub popu-
lations. If we compare estimated years of life lost to disability as per-
centage of the total health loss to hip fractures for women only, we find
it to constitute 56% as compared to 57% in the Tromso study and 58%
in the Swedish mammography study.
For comparability, we have used the GBD methodology and calcu-
lated years of life lost based on the years of remaining life from the
Coale study as our base case [26]. The Coale life expectancy of
82.5 years is generated from Japanese women and is higher than the
average life expectancy in most countries, including Norway. The GBD
group argues for using the Coale estimates because these estimates are
viewed as a maximum achievable goal [38]. Standardisation of life
expectancy also makes comparisons across studies from different
countries easier. As the life expectancy in these Japanese women is
higher than the average life expectancy in Norway, choosing the Nor-






















































Fig. 3. Future loss of health (DALYs) and costs projected based on different demographic and fracture rate assumptions.
GDB life expectancy (Coale 1989) and GDB disability weights (Haagsma et al. 2015) GDB life expectancy (Coale 1989) and IOF disability weights

















































Fig. 4. Effect of choice of disability weights and life expectancy on future burden.
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estimated health loss by 60%, on average. The choice of the Coale life
expectancy as a standard has been criticized by Williams [39], among
others, for generating unrealistically high, “fictional” estimates of
burden. According to Williams, actual local estimates would be pre-
ferable. For estimations of potential health gained by specific inter-
ventions, estimates based on the Norwegian mortality tables are re-
commended [39,40].
Our estimates of future burden are country specific, countries with a
different fracture rate or a different demographic development will
have different results. Scandinavia and Oslo in particular has had a very
high incidence rate of hip fractures, this will limit the external validity
of our projections. However, contributing to the increased burden is the
ageing of the population. To the degree that other countries are ex-
periencing population ageing, it is reasonable to assume that this will
lead to an increased burden, even in countries with a lower fracture
rate.
A strength of this study is the very robust data on fracture rate and
demographic change found in the Norwegian registries. Similarly, we
also have robust data on the cost of a hip fracture event, although some
assumptions were required.
A potential limitation is that we have used an overall estimate of
cost after hip fracture rather than an age specific estimate. Although
costs vary with age and may be observed to increase with increasing
age, this variation seems to disappear when controlling for the cost
incurred by age and sex matched controls [35]; if this holds true, our
approach is appropriate. However, if the observed decline in hip frac-
ture rates reflects a healthier group of older people, it is possible that
these potentially fitter individuals will experience less functional de-
cline following the fracture event and consequently require fewer (or
shorter) stays in institutions. If this is the case, we may be over-
estimating the future cost. Another option would be that the fractures
occur later in life on average, but because life expectancy also increases,
it could still result in an increased burden of hip fractures [41].
The future is unknown and any projection can only reflect best
available evidence at the time it is made. The cause of the decline in the
fracture rate observed in the previous period is unknown, complicating
a best guess of what will happen in the future. A Study from Denmark
found that increased uptake of anti-osteoporosis medication was un-
likely to explain the observed decline [42]. Some have speculated that
the decrease is due to increasing body mass, as body fat acts as a
cushion for the hip in the event of a fall. Should the fracture rate again
start to increase due to unfavourable lifestyle factors, e.g., poor diet or
an increasingly sedentary lifestyle (in a similar manner to obesity and
diabetes), our projections will underestimate future burden.
Despite the availability of effective preventative measures, uptake
of medications remains moderate to poor [43–45], possibly due to in-
creased focus on rare side effects from bisphosphonates such as atypical
fractures and osteonecrosis of the jaw. Preventive measures may further
reduce the fracture rate or they may improve health outcomes, so that
mortality or disability after fracture is reduced. Any reduction in dis-
ability is also likely to reduce cost, as loss of function contributes
greatly to cost after fracture [46].
Despite declining hip fracture rates, the health and economic
burden of hip fractures are very likely to increase by 2040. This in-
creasing burden of hip fractures may warrant an increased focus on
preventative and rehabilitation efforts.
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